Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Disruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery

Objective

EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed. The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body. The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee. As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-ACCELERATOROPEN-01

See all projects funded under this call

Coordinator

CRANNMED LTD
Net EU contribution
€ 2 488 572,80
Address
TRUSKEY BARNA
H91XW6Y Galway
Ireland
SME
Yes
Region
Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 555 104,00